HRL
39
15
VLO
40
-2
PRU
57
-3
MTB
63
-2
JWN
40
-2
AXP
66
2
IR
63
3
LB
34
8
ICE
59
-3
EXR
57
-2
CMCSA
48
2
GIS
26
3
MA
55
-7
STI
47
-12
JPM
63
-4
DLTR
34
-4
SYF
85
2
NTAP
64
2
DE
46
3
HIG
67
4
HRL
39
15
VLO
40
-2
PRU
57
-3
MTB
63
-2
JWN
40
-2
AXP
66
2
IR
63
3
LB
34
8
ICE
59
-3
EXR
57
-2
CMCSA
48
2
GIS
26
3
MA
55
-7
STI
47
-12
JPM
63
-4
DLTR
34
-4
SYF
85
2
NTAP
64
2
DE
46
3
HIG
67
4
Financhill
Back

Cartesian Therapeutics 10K Form

Sell
26

RNAC
Cartesian Therapeutics

Last Price:
16.80
Seasonality Move:
13.13%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive RNAC News And Ratings

See the #1 stock for the next 7 days that we like better than RNAC

RNAC Financial Statistics

Sales & Book Value

Annual Sales: $26M
Cash Flow: $7.49M
Price / Cash Flow: 0
Annual Sales: $0.03
Price / Book: 627.6

Profitability

EPS (TTM): -54.95000
Net Income (TTM): $-244.83M
Gross Margin: --
Return on Equity: 0%
Return on Assets: -79.52%

Cartesian Therapeutics Earnings Forecast

Key Cartesian Therapeutics Financial Ratios

  • The Research & Development expenses have been 276.26% of Revenue.
  • The Interest Expense is -1.29% of Operating Income.
  • The Net Earning history of RNAC is -844.91% of Total Revenues.
  • Per Share Earnings over the last 10 years have been positive in 6 years.

Cartesian Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: RNAC
Website: cartesiantherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 10.7
Quick Ratio: 10.51

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

RNAC Technical Analysis vs Fundamental Analysis

Sell
26
Cartesian Therapeutics (RNAC) is a Sell

Is Cartesian Therapeutics a Buy or a Sell?